ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 941,64
0,00%
Dow Jones
44 882,13
0,38%
DAX
21 730,58
0,00%
Brent Oil
75,895
-0,20%
Bitcoin
104 301,91
-0,41%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Avidity Biosciences Inc (RNA)

  7. Avidity Biosciences Inc (RNA) Actualités

RNA

Avidity Biosciences (RNA)

Avidity Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RNA
DateHeureSourceTitreSymboleSociété
24/01/202502h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
22/01/202522h25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RNAAvidity Biosciences Inc
20/01/202522h05PR Newswire (US)Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RNAAvidity Biosciences Inc
09/01/202501h04Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
08/01/202515h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
08/01/202515h00PR Newswire (US)Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025NASDAQ:RNAAvidity Biosciences Inc
26/11/202416h00PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferenceNASDAQ:RNAAvidity Biosciences Inc
14/11/202415h39Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RNAAvidity Biosciences Inc
13/11/202422h40Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RNAAvidity Biosciences Inc
12/11/202413h00PR Newswire (US)Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology InnovationsNASDAQ:RNAAvidity Biosciences Inc
07/11/202422h05PR Newswire (US)Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent HighlightsNASDAQ:RNAAvidity Biosciences Inc
31/10/202414h00PR Newswire (US)Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024NASDAQ:RNAAvidity Biosciences Inc
30/10/202413h00PR Newswire (US)Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular DystrophyNASDAQ:RNAAvidity Biosciences Inc
03/10/202413h00PR Newswire (US)Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)NASDAQ:RNAAvidity Biosciences Inc
05/09/202415h00PR Newswire (US)Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness MonthNASDAQ:RNAAvidity Biosciences Inc
28/08/202415h00PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:RNAAvidity Biosciences Inc
19/08/202415h00PR Newswire (US)Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:RNAAvidity Biosciences Inc
15/08/202422h43Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RNAAvidity Biosciences Inc
15/08/202402h30PR Newswire (US)Avidity Biosciences Announces Pricing of Upsized Public Offering of Common StockNASDAQ:RNAAvidity Biosciences Inc
09/08/202423h02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RNAAvidity Biosciences Inc
09/08/202422h23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RNAAvidity Biosciences Inc
09/08/202422h05PR Newswire (US)Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent HighlightsNASDAQ:RNAAvidity Biosciences Inc
09/08/202413h00PR Newswire (US)Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping inNASDAQ:RNAAvidity Biosciences Inc
05/08/202415h00PR Newswire (US)Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal OfficerNASDAQ:RNAAvidity Biosciences Inc
20/06/202415h00PR Newswire (US)Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD DayNASDAQ:RNAAvidity Biosciences Inc
17/06/202422h05PR Newswire (US)Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:RNAAvidity Biosciences Inc
14/06/202402h00PR Newswire (US)Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common StockNASDAQ:RNAAvidity Biosciences Inc
12/06/202422h01PR Newswire (US)Avidity Biosciences, Inc. Announces Proposed Public Offering of Common StockNASDAQ:RNAAvidity Biosciences Inc
12/06/202413h00PR Newswire (US)Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular DystrophyNASDAQ:RNAAvidity Biosciences Inc
29/05/202422h05PR Newswire (US)Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research CongressNASDAQ:RNAAvidity Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:RNA

Dernières Valeurs Consultées

EU
RI
Pernod Ricard
COIN
ADAUSD
Cardano
NYSE
MCD
McDonalds
EU
BEL20
Bel 20
COIN
DOGEUSD
Dogecoin
NYSE
DIS
Walt Disney
EU
PX4
SBF 120
EU
CAP
Capgemini
EU
VK
Vallourec
EU
AI
Air Liquide
NASDAQ
GOOGL
Alphabet
COIN
XRPUSD
Ripple
EU
BNP
BNP Paribas
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces